; (B) rotating mirror, drive shaft (1), window (2) , transducer (3), n (4); (C) circular electronic array, preamplifiers (1) (fig 3) , but has yet to be fully compared with conventional 2D imaging. Its main role may prove to be in perfusion studies using ultrasonic contrast agents.
Research is being conducted on the reconstruction of 3D intravascular images in the coronary arteries. This requires collection of a set of 2D images at equidistant points along the coronary artery, and is carried out by moving the catheter a known distance between each B scan image78 (fig 4) . The technique has potential in the detailed exploration of the characteristics of plaque and in the assessment of the coronary artery post-angioplasty. access to the ultrasound data earlier in the processing path before signal manipulation. Unfortunately in many instances gaining access to the ultrasound data early in the ultrasonic processing path is dependent on the goodwill of the ultrasound manufacturer. In addition, some of the larger ultrasonic manufacturers work with the analogue signal till late in the signal path, necessitating access to a high-speed digitiser and concomitant computer facilities to capture and store'the data. Alternatively a method which bypasses all this off-line analysis has now been implemented on-line by one company (Hewlett Packard, USA) which permits a region-of-interest (ROI) to be interactively chosen and the real time variation of integrated backscatter (IB), a parameter calculated from the RF data, to be continuously displayed on the ultrasound screen.
Without access to the RF data, the image sequence can be digitised at the end of the signal-processing path using a frame-grabber connected to the scanner video output and the variation in grey-scale intensity over a ROI calculated using standard software image analysis packages.9-1 In some instances, for an individual machine application and set-up it may be possible to use test phantoms to measure and compensate results for the effect of some of the non-linear processes which occur within the ultrasound machine. Because differences in processing paths occur not only between machines from individual manufacturers but also between different models and application set-ups, this can prove to be a time-consuming exercise. Figure 5 illustrates several of the non-linear processes which occur within an ultrasound machine and which result in the. dynamic range of the echo signals being compressed from 100 dB to 20 dB. These processes are time gain compression (TGC), logarithmic compression, demodulation, and scan conversion compression.
ANALYSIS OF RF BACKSCAT-TER FROM THE MYOCARDIUM
A parameter calculated from the backscatter reflected from the myocardium has been shown to be a discriminator between normal and infarcted myocardium."2 The parameter, integrated backscatter, is the ratio of the energy backscattered in the acoustical signal arising from the tissue volume of interest divided by that from a reference reflector. For cardiological application, no obvious choice of an anatomical reference reflector exists, although several authors have used the magnitude of the pericardial echo,'3 14 the magnitude of echoes from the blood pool, '5 tissue integrity than the dynamics of wall thickening.?7 In dilated or hypertrophied cardiomyopathies an increase in the magnitude of integrated backscatter was also observed2831 and a reduction in the normal cyclic variation of integrated backscatter.2
Despite the large amount of clinical data which is currently available, of which a few are cited above, integrated backscatter as an indicator of tissue viability is still largely not used as a routine clinical tool. Several factors contribute to this. Firstly, cyclic variation within the myocardium has almost exclusively been observed only from the precordial long and short axis views.33 In a recent study, however, cyclic variation from the myocardium was shown to be present when measured from the apical two and four chamber precordial views of the heart, although in these views the maximum in integrated backscatter is not always coincident with end diastole nor the minimum with end systole. 34 Time (1 cardiac cycle) Figure 6 Variation of integrated backscatter echo signal over a cardiac cycle erties of microbubbles, have been used to enhance the power of Dop from blood. Myocardial contrast es raphy is a relatively new method f myocardial perfusion.'5 It has the I provide information on myocardia which perfectly complements the anatomical, functional, and haemodynamic information derived from routine echo studies. This technique was first described with intra-aortic and intracoronary injections of contrast microbubbles to demonstrate myoIntegrated cardial perfusion.'6 When the microbubbles backscatter enter the myocardium they cause an increase of backscattered ultrasound energy (power) and hence raise the myocardial grey level intensity in the image (fig 7) .
Early contrast agents were derived by agitation of solutions such as indocyanine green, saline, dextrose, hydrogen peroxide, and blood to produce free gas bubbles of air. ' A saccharide-based agent, SHU 508A Levovist (Schering AG Laboratories, Berlin), has diameters ranging from 2 to 8 Um. There are on average 6 to 7 x 108 bubbles/ml with a mean diameter of 2,m. The recommended dose is 5 pll/kg. The agent is reported to be able to withstand pressures up to 300 mmHg, an important consideration in myocardial imaging. The gas is exhaled from the body and does not seem to have toxic effects.
Quantison (Andaris, Nottingham) is another HSA gas encapsulated agent with microbubbles of a mean diameter of 3-2 pm with less than 2% having diameters greater than 6,m. The thickness of the shell of this agent can be varied between 100 and 200 nm to enable it to withstand high pressure. Andaris are also currently developing another agent, Quantison Depot and marketing this as a myocardial perfusion agent.
A third type of agent in addition to free and encapsulated bubbles is the phase-change agent which is injected into the body as a liquid and at body temperature converts into microbubbles.45 46 The agent (Echogen, QW3600) developed by Sonus Pharmaceuticals (Bothell, Washington, USA) is a perfluoropentane emulsion which vaporises to give bubbles with diameters of 2-5 jm. After intravenous injection, it clears from the blood stream in 30 to 40 minutes but attaches to the endocardium giving prolonged enhancement. The recommended dose for humans is 0 1 ml/kg.The above examples of contrast agents are quoted to illustrate the types known to be under development. There are at least 12 contrast agents in the preliminary stages of evaluation. An intravenous agent for myocardial perfusion has still to reach a stage of common acceptance. After LAD PTCA Peak= 13 T = 65.5 ' 8 Before LAD PTCA C,,;, . Figure 9 Wash-in and wash-out perfusion curves of a microbubble agent (Albunex) in the myocardium before and after angioplasty (PTCA).
Most systems developed in individual centres have used small micro-computers and video frame grabbers. These acquire analogue video data from the video output on the ultrasound scanner. Once a series of echocardio- 15 20 Frame number 15 20 Frame number * Left ventricle Myocardium Figure 10 Variation of integrated backscatter and mean frequency of the ultrasound signals from the left ventricular chamber and myocardium after injection of a microbubble contrast agent (Albunex). Each frame corresponds to one cardiac cycle: frames are triggered from the R wave of the electrocardiogram.
graphic frames have been stored in the computer memory then an area of interest may be established on the image and changes in grey level as a result of contrast injection evaluated using video densitometry. Unfortunately, as noted earlier, there is a large amount of distortion and compression of ultrasound data by the imaging system. This data distortion has meant that quantitative analysis is difficult because a non-linear relation exists between back-scattered ultrasound intensity and grey level display. Furthermore, the comparative low contrast resolving power of current imaging systems means that the small changes in backscatter echo intensity from the myocardium that occur as a result of intravenous contrast injection are not detectable.
To facilitate quantitative analysis of perfusion, temporal changes in myocardial contrast enhancement have been analysed. An area of interest may be positioned over any portion of the image and changes in the grey level values plotted against time. This provides a contrast wash-in and wash-out curve. These curves have been analysed in a number of different ways and parameters such as the peak grey level, wash-out half-time, area under curve and wash-in time have been utilised by several authors.50-54 An example of a perfusion curve is shown in figure 9 .
Methods based upon backscatter signal intensity and grey level data seem adequate for intracoronary injections of contrast where changes in signal amplitude are relatively large. However, as previously mentioned, they appear insensitive for the detection of the very small quantities of microbubbles appearing in the myocardium after intravenous injection of transpulmonary agent. In addition, they have only been tested in experimental situations where image quality was optimum.55 56 Analysis not only for changes in backscattered amplitude, but also for any changes in its frequency spectrum that might have occurred as a result of interaction with contrast microspheres. 57 From an instrumentation point of view, it may be technically easier to create methods for analysis of small changes in frequency than small changes in amplitude. The backscatter from Albunex is frequency dependent and its resonant frequency appears to be within the bandwidth of cardiac diagnostic imaging transducers. Therefore, it is not surprising that significant changes in the mean frequency of the scattered signal may be seen after Albunex injections.58 Figure 10 illustrates the variation in myocardial integrated backscatter and the shift in mean frequency of the backscattered signal after Albunex was given to one patient. Frames correspond to cardiac cycles, frame acquisition being triggered from the R wave of the ECG. An increase in myocardial integrated backscatter is seen, together with a fall in mean frequency of the backscattered signal. This latter phenomenon is thought to result from resonant absorption of certain parts of the transmitted ultrasound spectrum,58 which causes a net shift in the backscattered signal.
Pulse-echo grey shade and colour Doppler flow imaging techniques are being developed to extract infornation from the second harmonic of the backscattered signal from microbubbles.59 The second harmonic occurs at twice the frequency of the normal backscattered signal and is due to non-linear oscillation of the bubbles. A second harmonic component is not present in the backscattered signal from tissue and hence by examining it the microbubble signal is more clearly seen. Second harmonic imaging is expected to enhance the signal from bubbles in blood vessels by a factor in excess of 20 dB. Echocardiography has now been largely accepted as the gold standard for the evaluation of valvar heart disease, congenital heart disease, cardiomyopathies, pericardial disease, and left ventricular function. However, the technique has yet to make a significant impact upon the management of patients with ischaemic heart disease and most patients seen in any adult cardiology centre have ischaemic heart disease. The advent of myocardial contrast echocardiography should extend the role of echocardiography significantly into the assessment of ischaemic heart disease.
